Brought to you by 
Drug discovery company Recursion Pharmaceuticals raises $12.9mm in Series A round; adds $2.2mm to end round at $15.1mm
22 Apr 2022
Executive Summary
Recursion Pharmaceuticals LLC (novel drug screening platform) raised $12.9mm in its Series A financing round led by Lux Capital. Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Wild Basin Investments, and other angel investors also participated.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Drug discovery company Recursion Pharmaceuticals raises $12.9mm in Series A round; adds $2.2mm to end round at $15.1mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice